cv 3988 has been researched along with 6-ketoprostaglandin f1 alpha in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Okano, S; Tagawa, M; Urakawa, N | 1 |
| Kolaczkowska, E; Plytycz, B; Seljelid, R; Shahzidi, S; van Rooijen, N | 1 |
2 other study(ies) available for cv 3988 and 6-ketoprostaglandin f1 alpha
| Article | Year |
|---|---|
Effect of platelet activating factor antagonist (CV-3988) on 6-keto-PGF1 alpha and thromboxane B2 in dogs with experimental endotoxin-induced shock.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Dog Diseases; Dogs; Hemodynamics; Phospholipid Ethers; Platelet Activating Factor; Shock, Septic; Thromboxane B2 | 1995 |
Early vascular permeability in murine experimental peritonitis is co-mediated by resident peritoneal macrophages and mast cells: crucial involvement of macrophage-derived cysteinyl-leukotrienes.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Capillary Leak Syndrome; Capillary Permeability; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Cysteine; Diterpenes; Eicosanoids; Enzyme Induction; Ginkgolides; Histamine Release; Indoles; Indomethacin; Isoenzymes; Lactones; Leukotriene C4; Leukotrienes; Lipoxygenase Inhibitors; Macrophages, Peritoneal; Male; Mast Cells; Membrane Proteins; Mice; Mice, Inbred BALB C; Mice, Mutant Strains; Nitrobenzenes; Peritonitis; Phospholipid Ethers; Platelet Activating Factor; Prostaglandin-Endoperoxide Synthases; Quinolines; Sulfonamides; Thioglycolates; Zymosan | 2002 |